Wall Street &
Healthcare
Two megasectors, one playbook: capture the regulator, gut the consumer protection, privatize the public system.
The financial industry and the healthcare industry do not look alike. One trades derivatives in glass towers on the Hudson; the other runs dialysis clinics in strip malls across the Sun Belt. But follow the money and they become indistinguishable. Both spend hundreds of millions per year on federal lobbying. Both rotate their executives through the agencies that regulate them. Both have perfected the art of blocking reform after a crisis, then resuming the behavior that caused it. In 2025, these two sectors spent a combined $1.58 billion on lobbying — more than the GDP of a dozen sovereign nations.
The Ledger examined twenty years of lobbying disclosures, campaign finance records, revolving-door employment data, and regulatory enforcement actions across both sectors. We traced money from corporate treasuries through trade associations and Super PACs into the campaign accounts of the committee members who write the rules. We tracked former regulators into industry jobs and measured the enforcement gaps that followed. The pattern is the same in both industries: spend to capture, capture to deregulate, deregulate to profit.
This chapter covers the financial industry — from the 2008 crisis through crypto's rise — and the broader healthcare sector beyond pharmaceuticals: insurers, hospitals, pharmacy benefit managers, and the managed care companies that now control more than half of Medicare. The data comes from Senate lobbying disclosures, FEC filings, OpenSecrets, CMS records, and federal enforcement databases.
The Financial Industry
The FIRE sector — finance, insurance, and real estate — spent $636.4 million on federal lobbying in 2024 and $711 million in 2025. Securities and investment firms alone accounted for $195 million, a 26% increase in a single year. JPMorgan led individual corporate spenders at $8.05 million, followed by Goldman Sachs at $4.69 million. These numbers represent only registered lobbying; they do not include campaign contributions, dark money, or the personal political spending of executives like Kenneth Griffin, who spent $100 million in 2024 alone and more than $250 million over his career.
The financial sector's lobbying machine does not operate in bursts. It is permanent infrastructure. In the decade before the 2008 financial crisis, the industry spent $2.7 billion on lobbying and over $1 billion in campaign contributions. Companies that received $295 billion in TARP bailout funds had collectively spent $114 million on lobbying in the years prior. The investment in political influence paid for itself many times over — first in the deregulation that enabled the crisis, then in the bailout that cushioned its consequences.
Dodd-Frank: The Template
The Dodd-Frank Act of 2010 was supposed to prevent the next crisis. The financial industry treated it as a lobbying opportunity. During the legislative fight, banks deployed 3,000 lobbyists — six for every member of Congress — and spent $27.3 million in just three months. When the bill passed anyway, the industry simply shifted its spending to the rulemaking process. In the three years after passage, annual lobbying exceeded the pre-passage totals: $55 million, then $61 million, then $61 million again. The lesson was clear: if you cannot kill a law, you can gut its implementation.
The strategy bore fruit in 2018, when $400 million in cumulative lobbying secured a rollback that raised the “too-big-to-fail” threshold from $50 billion to $250 billion in assets. Among the most aggressive advocates was Greg Becker, CEO of Silicon Valley Bank, who personally lobbied for the higher threshold. Five years later, SVB collapsed — the second-largest bank failure in American history — at exactly the asset level that would have kept it under enhanced federal supervision had the threshold not been raised.
The CFPB Assault
The Consumer Financial Protection Bureau was created by Dodd-Frank to serve as a watchdog for ordinary Americans against predatory financial practices. The industry targeted it immediately. The U.S. Chamber of Commerce spent $30 million campaigning to restructure the agency. When Mick Mulvaney was appointed acting director in 2017, he requested a $0 budget from Congress — literally asking for no money to operate the agency he led. In February 2025, OMB Director Russell Vought ordered the CFPB to cease all supervisory work entirely. The estimated cost to consumers of the weakened oversight exceeds $15 billion.
Crypto: The New Money
The cryptocurrency industry has replicated Wall Street's playbook at unprecedented speed. Lobbying spending increased 1,386% in six years — from $2.72 million in 2017 to $40.42 million in 2023. But lobbying was only the beginning. Fairshake, the industry's Super PAC, raised $195 million for the 2024 cycle and achieved a 91% win rate, accounting for nearly half of all corporate political dollars spent that year. The PAC specifically targeted progressive members who had called for stronger crypto regulation: Katie Porter in California, Jamaal Bowman in New York, and Cori Bush in Missouri. All three lost.
The Revolving Door and Private Equity
The SEC's revolving door is among the most active in government. A total of 419 former employees filed 1,949 post-employment disclosure statements — and academic research has documented that regulators are 44.7% less likely to bring enforcement actions against banks that maintain active lobbying operations. The message to would-be enforcers is unmistakable: these companies will be your future employers.
Private equity has leveraged this dynamic to protect its most lucrative advantage. The industry spent $625 million on political influence in 2020 alone, primarily to preserve the carried interest loophole — a tax provision that allows fund managers to pay capital gains rates on what is effectively labor income, saving the industry an estimated $2 billion per year. When the Inflation Reduction Act threatened to close the loophole, Senator Kyrsten Sinema — who had received $500,000 from private equity donors — demanded its removal from the bill. The $14 billion closure provision was stripped. The loophole remains.
The Money Loop
Six steps reveal how profits become lobbying, lobbying blocks reform, and blocked reform protects profits — in both Wall Street and healthcare.
The Premium Extraction
It starts with the money Americans have no choice but to pay. Health insurance premiums have risen 47% over the past decade while wages grew 27%. Medicare Advantage plans — 52% of all Medicare enrollment — overcharge the federal government by an estimated $600 billion since 2003. The money flows in one direction: out of paychecks, out of the Treasury, and into corporate balance sheets. UnitedHealth posted $2.3 billion in profit in Q3 2025 alone.
The Lobbying Wall
Those profits fund the lobbying apparatus that prevents reform. The health sector spent $868 million on federal lobbying in 2025 — an all-time record, driven by Medicaid cut battles. The financial sector added another $711 million. Combined, these two industries deployed more than $1.5 billion in a single year to shape the laws that govern them. The American Hospital Association alone spent $32 million. Blue Cross Blue Shield retained 100 lobbyists just for Medicare Advantage.
The Reform Kill
The lobbying works. When Congress considered the No Surprises Act, the private-equity-owned physician staffing industry funneled $54 million through a dark money front called Doctor Patient Unity to gut the bill. When the Dodd-Frank Act threatened Wall Street, banks deployed 3,000 lobbyists — six for every member of Congress — and spent $27.3 million in just three months. After Dodd-Frank passed anyway, the industry spent $55 million, then $61 million, then $61 million again on implementation lobbying. The spending after the law exceeded the spending to block it.
The Regulatory Capture
When lobbying alone is not enough, both industries place their own people inside the agencies meant to police them. At the SEC, 419 former employees filed 1,949 disclosure statements — and research shows regulators are 44.7% less likely to enforce against banks that lobby. At CMS, 53% of departing officials leave for the health industry. Twenty-four of fifty state insurance commissioners came from the industry they regulate. The referees are former players.
The Payout
The captured regulators look the other way, and the profits flow. Private equity firms save $2 billion per year through the carried interest loophole — Senator Sinema took $500,000 from PE firms, then demanded a $14 billion closure of the loophole be removed from the Inflation Reduction Act. The three largest PBMs control 80% of the pharmacy market; the FTC has sued all three for inflating insulin prices. The cycle completes: profits fund lobbying, lobbying blocks reform, blocked reform protects profits.
The Cycle Repeats
Crypto showed how fast the playbook scales. Industry lobbying surged 1,386% in six years — from $2.72 million in 2017 to $40.42 million in 2023. Fairshake PAC raised $195 million and achieved a 91% win rate in 2024, accounting for nearly half of all corporate political dollars that cycle. They targeted and defeated progressive members Katie Porter, Jamaal Bowman, and Cori Bush. Wall Street learned this playbook decades ago. Healthcare perfected it. Crypto is running it at startup speed.
“The spending after Dodd-Frank passed exceeded the spending to block it. The industry learned: if you can't kill a law, you can gut its implementation.”
The Ledger Analysis, Senate Lobbying Disclosures 2009-2013
Healthcare Beyond Pharma
The pharmaceutical industry gets the headlines, but it is only one piece of the health sector's political machine. The broader healthcare industry — insurers, hospitals, managed care organizations, and pharmacy benefit managers — is the single largest lobbying sector in the United States. In 2025, total health sector lobbying hit $868 million, a record driven by the fight over proposed Medicaid cuts. More than 1,834 registered lobbyists worked the sector that year.
The Insurance Machine
Health insurers have built one of the most sophisticated influence operations in Washington. Blue Cross Blue Shield spent $27.15 million on lobbying and deployed 100 lobbyists focused specifically on Medicare Advantage. AHIP, the insurance industry trade group, spent a record $13.06 million — and that figure does not include the $86.2 million AHIP secretly funneled to the U.S. Chamber of Commerce to fund anti-Affordable Care Act advertising campaigns. UnitedHealth Group spent $9.93 million in registered lobbying while posting billions in quarterly profit.
The hospital lobby matches the insurers in scale if not sophistication. The American Hospital Association spent $29 million in 2024 and $32 million in 2025. The Federation of American Hospitals, which represents for-profit hospital chains, illustrates the revolving door in miniature: 19 of its 23 registered lobbyists previously held government positions.
Medicare Advantage: The $600 Billion Overcharge
Medicare Advantage is the crown jewel of healthcare industry capture. Private insurers receive per-enrollee payments from the federal government to manage care for Medicare beneficiaries — and they have systematically inflated those payments through a practice known as upcoding, in which patients are diagnosed with more severe conditions than they actually have. Since 2003, overpayments have exceeded $600 billion. Projections show they will surpass $1 trillion over the next decade.
To protect this revenue stream, the industry deployed more than 220 lobbyists focused on Medicare Advantage policy. UnitedHealth alone received an estimated $8.7 billion in excess payments. The Better Medicare Alliance — an industry-funded advocacy group — spent over $13.5 million on advertising campaigns promoting Medicare Advantage to seniors and lawmakers. The message is always the same: beneficiaries love the program. The overpayments are never mentioned.
PBMs, Dark Money, and Surprise Billing
Pharmacy benefit managers — the middlemen who negotiate drug prices between manufacturers and insurers — have become one of the most concentrated and opaque forces in healthcare. The three largest PBMs control 80% of the market. PCMA, their trade group, doubled its lobbying to $17.5-18 million as the Federal Trade Commission brought suit against all three for inflating insulin prices. The FTC's complaint alleges that PBMs systematically steered patients toward higher-cost insulin products to increase their own rebate revenue.
When Congress moved to ban surprise medical billing — the practice of charging patients out-of-network rates for emergency care — the private equity firms that own physician staffing companies deployed more than $100 million in dark money to weaken the legislation. A front group called Doctor Patient Unity spent $54 million on advertising without disclosing that its sole funders were TeamHealth and Envision Healthcare, two PE-owned staffing firms that profited directly from the billing practices the law targeted. The No Surprises Act eventually passed, but the arbitration mechanism was designed to favor providers over patients.
UnitedHealth: Case Study in Scale
No company better illustrates the scale of healthcare industry power than UnitedHealth Group. In December 2024, the killing of its insurance unit CEO became a cultural flashpoint — a reflection of public fury at an industry that denies claims, inflates costs, and spends billions on political influence. By 2025, the Department of Justice had opened both criminal and civil investigations into the company. UnitedHealth posted $2.3 billion in Q3 2025 profit — down from $6.1 billion in the prior year, reflecting legal costs and increased regulatory scrutiny.
The Healthcare Revolving Door
The revolving door in healthcare is not a side effect. It is the mechanism. At CMS — the agency that administers Medicare and Medicaid, overseeing more than $1.5 trillion in annual spending — 53% of departing officials leave for positions in the health industry. Twenty-four of fifty state insurance commissioners came from the industry they were appointed to regulate. The estimated consumer cost of this structural capture is $27 billion per year in overpayments, denied claims, and unenforced regulations.
Medicaid managed care — the outsourcing of state Medicaid programs to private insurers — represents the latest frontier. The program now exceeds $880 billion, with managed care organizations handling 52% of enrollment. Centene, the largest Medicaid MCO, has spent $26.9 million on political activity while settling overbilling claims in more than thirteen states for a cumulative total exceeding $1 billion. The company pays the settlements, increases its political spending, and continues to win new state contracts.
The Influence Network
The corporations, executives, and trade groups driving a combined $1.58 billion lobbying machine across finance and healthcare.
JPMorgan Chase
The largest U.S. bank by assets and the top individual lobbying spender in the financial sector. Led the industry fight against Dodd-Frank provisions.
Fairshake PAC
The crypto industry Super PAC that accounted for nearly half of all corporate political dollars in 2024. Targeted and defeated three progressive incumbents.
UnitedHealth Group
The largest health insurer in the U.S. Received an estimated $8.7 billion in excess Medicare Advantage payments. Under DOJ criminal and civil investigation in 2025.
Blue Cross Blue Shield
Deployed 100 lobbyists focused solely on Medicare Advantage. The single largest lobbying spender in the health insurance sector.
Kenneth Griffin / Citadel
Citadel founder and hedge fund billionaire. Over $250 million in career political spending. Emblematic of the megadonor class that dominates financial sector influence.
Centene Corporation
The largest Medicaid managed care company. Settled overbilling claims in 13+ states while maintaining one of the highest political spending profiles in the sector.
Methodology & Data Sources
All figures in this chapter are derived from publicly available data. Lobbying expenditure data comes from the Senate Lobbying Disclosure Act database and OpenSecrets.org. Medicare Advantage overpayment estimates reference MedPAC reports, CBO analyses, and peer-reviewed research published in health economics journals. Campaign finance data is sourced from the Federal Election Commission (FEC.gov). Revolving-door statistics are drawn from the Government Accountability Office, the Project on Government Oversight, and SEC post-employment disclosure filings. PBM market share and FTC enforcement data reference the FTC's 2024 interim staff report. Centene settlement figures are aggregated from state attorney general press releases. All numbers are illustrative aggregates for editorial purposes and should be verified against primary sources for citation.
Follow the Money
Explore the interactive money flow diagram to trace financial and healthcare lobbying dollars from corporate treasury to Capitol Hill and back.